Skip to main content

Table 2 Disease/medical specialty area to which the product relates

From: EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

Disease/specialty area

Number of FP7 product-related awards

Total EC funding across awards

Neonatal/paediatric

27

€ 144,697,453.51

Infection

22

€ 103,803,065.19

Cancer

19

€ 98,467,149.13

Cardiovacular

7

€ 53,059,136.35

Diabetes

7

€ 39,387,415.80

Neurology

5

€ 39,361,768.70

Rheumatology

5

€ 38,211,526.50

Neurodegenerative

4

€ 26,594,086.00

Immunology

4

€ 25,825,968.00

Genetic diseases

4

€ 22,702,610.55

Eye/ear

4

€ 20,227,976.98

Respiratory

3

€ 17,974,237.00

Orthopaedics

2

€ 17,649,160,30

Regenerative medicine

1

€ 11,935,340.00

Psychiatry

1

€ 5,994,380.00

Skin

1

€ 4,961,654,00

Gastroenterology

1

€ 4,951,792.40

Brain

1

€ 4,865,656,00

Endocrinology

1

€ 3,308,154.00

Urology

1

€ 2,892,869.00

Total

120

€ 686,871,399.41